Advertisement

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Business

Seres forms two microbiome pacts

by Michael McCoy
May 23, 2016 | A version of this story appeared in Volume 94, Issue 21

Seres Therapeutics will work with scientists at the University of Pennsylvania and Memorial Sloan Kettering Cancer Center on microbiome therapeutics. With Penn, the start-up will develop bacteria-based treatments for metabolic diseases including urea cycle disorders and inflammatory bowel disease. And Seres aims to support the translation of the cancer center’s discoveries into microbiome therapeutics that help patients undergoing hematopoietic stem cell transplantation and increase the efficacy of checkpoint inhibitors used in immuno-oncology.

Article:

This article has been sent to the following recipient:

0 /1 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.